<!doctype html>
<html lang="ja" prefix="og: http://ogp.me/ns#">
<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
	<title>校閲サンプル｜英文校正・校閲・添削、論文翻訳のNAI</title>
	<meta name="description" content="校閲サンプルのページです。英語論文の校正・校閲・添削ならエヌ・エイ・アイにお任せ下さい。有名ジャーナルの査読経験者やMD.、Ph.D.の保有者から、欧米出身の各分野に特化した経験豊富な校閲者を厳選しております。英文の校正・校閲・添削・翻訳・リバイス・リライト20年以上の実績、お客様満足度90％のサービスでアクセプトをサポートします。翻訳や従来型校閲サービスに加え新サービスを導入しております。文法チェックからプレゼンサポート、フルチェンジリライト(ネイティブ英語への大転換)、日本人科学翻訳者による校閲前下準備サポートまで行っております。無料お見積り承ります。" />
	<meta name="format-detection" content="telephone=no">
	<link rel="shortcut icon" type="image/vnd.microsoft.icon" sizes="16x16" href="/favicon.ico">
	<link rel="icon" href="/favicon.ico">
	<link rel="start" href="http://www.nai.co.jp/" title="ホーム">
	<link rel="stylesheet" href="../common/css/commons.css">
	<link rel="stylesheet" href="../common/css/contents/correction-sample.css">
	<link rel="stylesheet" href="../common/css/fonts.css">
	<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Merriweather+Sans|Lato:400,700,900">
	<script src="//ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
	<script src="//s3.amazonaws.com/nwapi/nwmatcher/nwmatcher-1.2.5-min.js"></script>
	<script src="/common/js/jquery/jquery.easing.1.3.js"></script>
	<script src="/common/js/module.js"></script>
	<!--[if lt IE 9]>
	<script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
	<script src="/common/js/selectivizr-1.0.2.min.js"></script>
	<![endif]-->
	<!--[if lt IE 7]>
	<script src="/common/js/DD_belatedPNG.js"></script>
	<script src="/common/js/PNGclass.js"></script>
	<![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-10019976-1', 'auto');
  ga('send', 'pageview');
</script>
</head>
<body id="content">
<script type="text/javascript">
	writeHeader("../","校閲サンプル｜");
</script>
	<div id="ttlBlock"><!-- ttlBlock -->
		<h2>校閲サンプル</h2>
	</div><!-- /ttlBlock -->
	<div id="pankuzu">
		<ul>
			<li><a href="/">英文・英語の校正・校閲・添削のNAIトップ</a></li>
			<li>校閲サンプル</li>
		</ul>
	</div>
	<div id="mainContentArea">
		<section class="box">
			<h3 class="secTtl"><span>原文</span></h3>
			<div class="textBox borderBox ocBox off">
				<p>Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.</p>
				<p>Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported.</p>
				<p>The patient was prescribed FTY720 1.25 mg once-daily for the past three years. Regular MRI and Gd-enhanced MRI examination was done every three months. </p>
				<div class="openBtn btn border"><span>続きを見る<i class="icon-cd"></i></span></div>
				<div class="openBox">
				<p>For the above described observational period, the patient has been free of Gd-enhanced lesions, indicating favorable result from fingolimod. Adverse events related to FTY720 included liver enzyme levels, and the increased cases of minor palpitations. Although its relationship to the use to FTY720 is yet unknown, the other event reported includes worsening of past symptoms from the past exacerbations, such as persisting numbness and pain in the limbs, headaches, taste disorder.</p>
				<p>This case demonstrated the clinical efficacy of fingolimod in reducing relapses in remitting MS patient, consistent with the established effects of fingolimod in Caucasian patients. However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720.</p>
				</div>
				<div class="closeBtn btn border"><span>閉じる<i class="icon-cu"></i></span></div>
			</div>
			<nav class="subPage b2">
				<ul>
					<li><a href="#c1"><span><i class="icon-ced"></i>プレミアム校閲のサンプルへ</span></a></li>
					<li><a href="#c2"><span><i class="icon-ced"></i>プレミアムEX校閲のサンプルへ</span></a></li>
					<li><a href="#c3"><span><i class="icon-ced"></i>フルチェンジリライトのサンプルへ</span></a></li>
					<li><a href="#c4"><span><i class="icon-ced"></i>日本人科学翻訳者による校閲前下準備サポートのサンプルへ</span></a></li>
				</ul>
			</nav>
		</section>
		<section id="c1">
			<h4 class="normalTtl"><span>プレミアム校閲</span></h4>
			<div class="textBox">
				<p>プレミアム校閲では、原文のスタイルを残した上で、文法・言い回し・単語の選択・ロジックなどを査読経験や論文執筆経験豊富な欧米のネイティブ校閲者が校閲します。</p>
				<div class="borderBox ocBox off">
					<p><span class="line">Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.</span><span class="cl_orange">(NOTE: I would suggest changing the underlined sentence to, “Fingolimod (FTY720) was shown to be effective in reducing relapses in patients with multiple sclerosis (MS) in the Caucasian population.”)</span></p>
					<p><span class="line">Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported. </span><span class="cl_orange">(NOTE: How do you think about changing the underlined sentence to, “We report the efficacy and safety of FTY720 in a 38-year-old, Japanese female patient with relapsing MS who was treated with FTY720 for the past 3 years.”?</span></p>
					<p>The patient was prescribed <b>FTY720 1.25 mg once-daily</b> for the past three years. Regular MRI and Gd-enhanced <b>MRI examinations were performed</b> every three months. </p>
					<div class="openBtn btn border"><span>続きを見る<i class="icon-cd"></i></span></div>
					<div class="openBox">
					<p><b>During the three-year observation</b> period, the patient has <b>not had</b> Gd-enhanced lesions, indicating <b>a</b> favorable result from fingolimod. Adverse events <b>included increased</b> liver enzyme <b>levels</b> and the increased <b>occurrences</b> of minor <b>heart</b> palpitations. <span class="line-t">Although its relationship to the use to FTY720 is yet unknown, the</span><b> Other reported adverse events of FTY720 include</b> worsening of <b>symptoms</b> from <b>past</b> exacerbations, such as persistent numbness and pain in the limbs, headaches, and<b> </b>taste disorder.</p>
					<p>This case demonstrated the clinical efficacy of fingolimod in reducing relapses in <b>a relapsing-remitting</b> Japanese MS patient, consistent with the established effects of fingolimod in Caucasian patients. <span class="line">However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720. </span><span class="cl_orange">(NOTE: How do you think about changing the underlined sentence to, “However, further studies with a greater number of MS patients are needed to study the cause and mechanisms of adverse effects that may not be directly related to the use of FTY720.”?)</span></p>
					</div>
					<div class="closeBtn btn border"><span>閉じる<i class="icon-cu"></i></span></div>
				</div>
				<p>原文を最大限に尊重しながらも、より読みやすく明瞭な英文となるように仕上げます。<br>
				<small>※プレミアム校閲は変更履歴及びコメント機能を使用した校閲も可能です。その際には、上記のNOTE部分はコメント機能を使用し挿入いたします。</small></p>
			</div>
			<nav class="btnArrowArea">
				<ul>
					<li><a href="/correction/normal.html"><span>プレミアム校閲の詳しい内容はこちら<i class="icon-dr"></i></span></a></li>
				</ul>
			</nav>
		</section>
		<section id="c2">
			<h4 class="normalTtl"><span>プレミアムEX校閲</span></h4>
			<div class="textBox">
				<p>プレミアムEX校閲では、プレミアム校閲の校閲に加え、原文のスタイルを残しながらも大幅に書き直す作業を行います。必要に応じて、文の結合や分離等のご提案をさせていただきます。</p>
				<div class="borderBox ocBox off">
					<p><span class="line">Fingolimod (FTY720) is effective in reducing relapses among the Caucasian population in a patient with MS. </span><span class="cl_orange">(Note: I suggest deleting the word "Caucasian" since there is no comparison to non-Caucasian patients.)</span></p>
					<p><span class="line">Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported. </span><span class="cl_orange">(Note: I suggest changing the underlined to "Here, we report the efficacy of treatment and the safety outcome of a patient (female, 38 years old) with relapsing multiple sclerosis (MS) who was treated with fingolimod (FTY720) for the past three years".)</span></p>
					<p>The patient was <b>administered</b> FTY720 (1.25 mg, <b>q.d.</b>) for the past three years. Regular MRI and Gd-enhanced MRI <b>was performed</b> every three months. </p>
					<div class="openBtn btn border"><span>続きを見る<i class="icon-cd"></i></span></div>
					<div class="openBox">
					<p><b>During the</b> observational period, the patient <b>did not show</b> Gd-enhanced lesions, <b>which indicated a</b> favorable result from <span class="line-t">fingolimod</span> <b>FTY720</b>. <span class="cl_orange">(Note: Drug names should be consistent throughout the text.)</span> Adverse events related to FTY720 included liver enzyme levels <span class="cl_orange">(Note: High or low?)</span>, and increased incidence of minor <b>heart</b> palpitations. <span class="line-t">Although its relationship to the use to FTY720 is yet unknown</span>, Other events reported includes a worsening of past symptoms <span class="line-t">from the past exacerbations</span>, such as persisting numbness and pain in the limbs, headaches, <b>and</b> taste disorder, <b>although the relationship of these symptoms to the use of FTY720 is unclear</b>.</p>
					<p>This case demonstrates the clinical efficacy of <b>FTY720</b> in reducing relapses in remitting MS patient, consistent with the established effects of <b>FTY720</b> in <span class="line-t">Caucasian</span> <b>MS</b> patients.<span class="cl_orange"> (Note: In the results paragraph, there was no mention of the efficacy of FTY720 in reducing relapses. I suggest adding this result.)</span> However, <b>further study is needed to clarify</b> the cause and the mechanisms of adverse effects that <b>have not been attributed directly to the </b>use of FTY720.</p>
					</div>
					<div class="closeBtn btn border"><span>閉じる<i class="icon-cu"></i></span></div>
				</div>
				<p><small>※プレミアムEX校閲は変更履歴及びコメント機能を使用した校閲も可能です。その際には、上記のNOTE部分はコメント機能を使用し挿入いたします。</small></p>
			</div>
			<nav class="btnArrowArea">
				<ul>
					<li><a href="/correction/premium_ex.html"><span>プレミアムEX校閲の詳しい内容はこちら<i class="icon-dr"></i></span></a></li>
				</ul>
			</nav>
		</section>
		<section id="c3">
			<h4 class="normalTtl"><span>フルチェンジリライト</span></h4>
			<div class="textBox">
				<p>フルチェンジリライトでは、ネイティブの英語と同等な英文に仕上げるため、文法・語彙選択・論文内容の校閲にとどまらず、原文のスタイルや構成等を根本的に書き換えるリライトを行います。</p>
			<h3 class="secTtl"><span>原文</span></h3>
			<div class="textBox borderBox ocBox off">
				<p>Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.</p>
				<p>Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported.</p>
				<p>The patient was prescribed FTY720 1.25 mg once-daily for the past three years. Regular MRI and Gd-enhanced MRI examination was done every three months. </p>
				<div class="openBtn btn border"><span>続きを見る<i class="icon-cd"></i></span></div>
				<div class="openBox">
				<p>For the above described observational period, the patient has been free of Gd-enhanced lesions, indicating favorable result from fingolimod. Adverse events related to FTY720 included liver enzyme levels, and the increased cases of minor palpitations. Although its relationship to the use to FTY720 is yet unknown, the other event reported includes worsening of past symptoms from the past exacerbations, such as persisting numbness and pain in the limbs, headaches, taste disorder.</p>
				<p>This case demonstrated the clinical efficacy of fingolimod in reducing relapses in remitting MS patient, consistent with the established effects of fingolimod in Caucasian patients. However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720.</p>
				</div>
				<div class="closeBtn btn border"><span>閉じる<i class="icon-cu"></i></span></div>
			</div>

				<h4 class="subTtl"><span>依頼内容</span></h4>
                <p>専用依頼フォームで以下の項目等を確認いたします。</p>
				<ul class="normalList mb30">
					<li>スペル：<span class="line-t">米国・英国</span>・どちらでも可</li>
					<li>動詞：<span class="line-t">受動態・能動態</span> → 状況に合わせて選択して欲しい。</li>
					<li>一人称代名詞: <span class="line-t">I</span>・We</li>
					<li>原稿のスタイル変更度合い：<span class="line-t">しっかり</span>・適度に</li>
					<li>言い回しまたは単語の変更度合い：しっかり・<span class="line-t">適度に</span></li>
					<li>原稿の流れに対する変更度合い：しっかり・<span class="line-t">適度に</span></li>
					<li>投稿規定と照合：希望する(＋20%追加料金発生)</li>
				</ul>
				<h4 class="subTtl"><span>納品原稿</span></h4>
				<div class="borderBox ocBox off">
					<p><b>Purpose</b>: Fingolimod (FTY720; trade name Gilenya, Novartis) is a sphingosine-1-phosphate structural analogue used to prevent autoimmune reactions. It has been shown to decrease relapses among the Caucasian population with multiple sclerosis (MS). The purpose of this study was to determine the efficacy and safety of FTY720, for a prior three year treatment period, in a 38-year-old female patient with relapsing MS.</p>
					<p><b>Methods</b>: The patient was prescribed FTY720 at 1.25 mg/day for three years prior. Routine magnetic resonance imaging (MRI) and gadolinium-enhanced MRIs were conducted on the patient every three months.</p>
					<div class="openBtn btn border"><span>続きを見る<i class="icon-cd"></i></span></div>
					<div class="openBox">
					<p><b>Results</b>: For the observational period of three years, the patient was free of lesions, indicating favorable results from fingolimod treatments. Adverse events related to FTY720 included increased liver enzyme levels, and increased episodes of minor palpitations. Additional symptoms which may not be related to FTY720 treatments included worsening of past symptoms, such as persistent numbness and pain in the limbs, headaches, taste disorders.</p>
					<p><b>Conclusions</b>: This case study demonstrated clinical efficacy of fingolimod for reducing relapses in a remitting MS patient. The result was in agreement with the reported effects of fingolimod treatments in Caucasian patients with MS. Further studies should be done to determine the cause and the mechanism of the adverse effects that may or may not be related to the use of FTY720.
</p>
					</div>
					<div class="closeBtn btn border"><span>閉じる<i class="icon-cu"></i></span></div>
				</div>
				<p><small>※実際の納品原稿は修正履歴及びコメント機能と使用した修正が挿入されておりますが、ここでは原文からの書き換えを分かりやすくするため、修正箇所を表示しておりません。</small></p>
			</div>
			<nav class="btnArrowArea">
				<ul>
					<li><a href="/correction/fullchange.html"><span>フルチェンジリライトの詳しい説明はこちら<i class="icon-dr"></i></span></a></li>
				</ul>
			</nav>
		</section>
		<section id="c4">
			<h4 class="normalTtl"><span>日本人科学翻訳者による校閲前下準備サポート</span></h4>
			<div class="textBox">
				<p>日本人科学翻訳者による校閲前下準備サポートは、校閲前の英文を構築する段階で、日本人科学翻訳者に対して、英語の表現方法等に関する質問や不明点を、日本語で確認することができます。多くの学術文書の翻訳経験を持つ翻訳者とともに英文を作り上げた後、校閲者によって英文法の最終的な校閲(カジュアル校正)を行います。※プレミアム校閲に変更することも可能です。</p>
				<h4 class="subTtl"><span>依頼原稿</span></h4>
				<div class="borderBox alignC pt20 pb20">
				<img src="/common/images/correction/fig_sample01.png" width="700" alt="納品原稿"/>
				</div>
				<h4 class="subTtl"><span>翻訳者からの納品原稿</span></h4>
				<div class="borderBox alignC pt20 pb20">
				<img src="/common/images/correction/fig_sample02.png" width="700" alt="翻訳者からの納品原稿"/>
				</div>
				<h4 class="subTtl"><span>カジュアル校正後納品原稿</span></h4>
				<div class="borderBox alignC pt20 pb20">
                <img src="/common/images/correction/fig_sample03.png" width="700" alt="納品原稿"/>
                </div>
			</div>
			<nav class="btnArrowArea">
				<ul>
					<li><a href="/correction/japreparation.html"><span>日本人科学翻訳者による校閲前下準備サポートの詳しい説明はこちら<i class="icon-dr"></i></span></a></li>
				</ul>
			</nav>
		</section>
	</div>
	<div class="pgTop">
		<a href="#wrap">校閲サンプル トップ<i class="icon-cu"></i></a>
	</div>
	<div class="contentContactBox"><!-- contentContactBox -->
		<div class="in">
			<div class="ttl m-f">ご依頼はこちら</div>
			<p>最短1時間でお見積り！</p>
			<div class="entryBtn hei70">
				<a href="/mitsumori/" title="英文の校正・校閲・添削のNAI　お見積り・正式発注"><img src="../common/images/common/btn-mitsumori02.png" width="320" height="70" alt="お見積り・正式発注はこちら"/></a>
			</div>
		</div>
		<div class="in">
			<div class="ttl m-f"><i><img src="/common/images/common/ico_first.png" width="20" alt="はじめてのお客様"/></i>はじめてのお客様</div>
			<p><b>初回割引</b>または<b>無料トライアル</b>から！</p>
			<div class="firstBtn hei70">
				<a href="/firsttime/" title="英文の校正・校閲・添削のNAI　はじめてのお客様へ"><img src="../common/images/common/btn-hajimete02.png" width="320" height="70" alt="はじめてのお客様は初回割引または無料トライアルのサービス"/></a>
			</div>
		</div>
		<div class="telBox">
			<p>お電話でのお問い合わせはこちら<span>営業時間.平日 9:30～18:00</span></p>
			<div class="tel"><span>Tel.</span>045-290-7200</div>
		</div>
	</div><!-- /contentContactBox -->
<script type="text/javascript">
	writeFooter("../");
</script>
</body>
</html>